Kymera Therapeutics, Inc. (KYMR)
$20.61
Rating:
Recommendation:
-
| Symbol | KYMR |
|---|---|
| Price | $20.61 |
| Beta | 1.664 |
| Volume Avg. | 0.69M |
| Market Cap | 1.144B |
| Shares () | - |
| 52 Week Range | 9.6-39.85 |
| 1y Target Est | - |
| DCF Unlevered | KYMR DCF -> | |
|---|---|---|
| DCF Levered | KYMR LDCF -> | |
| ROE | -36.41% | Strong Sell |
| ROA | -29.38% | Sell |
| Operating Margin | - | |
| Debt / Equity | 20.44% | Neutral |
| P/E | -7.21 | Strong Sell |
| P/B | 3.04 | Strong Buy |
Latest KYMR news
About
Download (Excel)Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.